PAPER. Increased Lymph Node Evaluation With Colorectal Cancer Resection
|
|
- Madeline Boyd
- 6 years ago
- Views:
Transcription
1 PAPER Increased Lymph Node Evaluation With Colorectal Cancer Resection Does It Improve Detection of Stage III Disease? Sachin S. Kukreja, MD; Enrique Esteban-Agusti, MD; Josè M. Velasco, MD; Tina J. Hieken, MD Hypothesis: Evaluation of 12 or more lymph nodes (LNs) with colorectal cancer (CRC) resection may not improve detection of stage III disease. Design: Retrospective review after intervention. Setting: Community teaching hospital. Patients: We evaluated 701 consecutive operative CRC cases ascertained from our Cancer Registry. Intervention: Patients undergoing resection before (n=553) a multidisciplinary initiative emphasizing the importance of LN counts were compared with those undergoing operation afterward (n=148). Main Outcome Measures: Number of LNs evaluated, proportion of patients with stage III disease, and proportion of patients with N1 vs N2 disease. Results: Demographic, tumor, and treatment variables were similar for both groups, except for younger age, fewer white patients, and more laparoscopic resections in the late period. Lymph node counts increased from a mean (SEM [median]) of 12.8 (0.3 [12]) to 17.3 (0.7 [16]) (P.001), with 53.0% of the early vs 71.6% of the late patients having at least 12 LNs examined. The proportion diagnosed as having stage III CRC was 204 of 553 (36.9%) for the early group vs 48 of 148 (32.4%) for the late group (P=.31). Among patients with positive LNs, the distribution of N1 and N2 disease was unchanged (early, 50.5% N1 and 49.5% N2; late, 54.2% N1 and 45.8% N2; P=.54). Conclusions: Increased LN retrieval does not identify a greater number of patients with stage III CRC nor does it increase the proportion of patients with positive LNs with N2 disease. Our data suggest that harvest of at least 12 LNs as a quality or performance measure appears unfounded. Arch Surg. 2009;144(7): Author Affiliations: Department of Surgery, Rush North Shore Medical Center (Drs Kukreja, Esteban-Agusti, Velasco, and Hieken), Skokie, Illinois; and Rush University Medical Center and Rush Medical College, Chicago, Illinois (Drs Kukreja, Velasco, and Hieken). COLORECTAL CANCER (CRC) is the third most common cancer among both male and female patients and the third leading cause of cancer-related death in the United States. 1 Of the estimated patients who will be diagnosed as having CRC in 2008, more than 80% will have locoregional disease at the time of diagnosis and will be offered potentially curative surgery. Since publication of the initial staging classification for CRC by Dukes, 2 regional lymph node (LN) status has been recognized as the most powerful prognostic factor for recurrence and overall survival for these patients. 2,3 Accurate LN staging also is important for determining prognosis and the need for adjuvant chemotherapy. 4 In addition, lymphadenectomy may be therapeutic; several studies have shown a positive association between the number of LNs removed and survival for patients with negative and positive LNs. 3,5-8 The concept of a threshold for a minimum acceptable number of LNs ( 12) with CRC resection was first introduced in 1990 by the World Congress of Gastroenterology. 3 More recently, this benchmark has been adopted as a quality measure for surgical practice by multiple organizations, including the American College of Surgeons Commission on Cancer, the American Society of Clinical Oncology, the College of American Pathologists, and the National Comprehensive Cancer Network, and several health insurance providers Controversy remains as to whether adoption of this standard will result in the intended improvement in patient outcome and whether it is an appropriate measure of quality of care. 7,13-15 Two recent, large population-based studies found that most patients with CRC (51%-63%) do not undergo an adequate resection with evaluation of at least 12 LNs. 16,17 Using the benchmark of evaluation of at least 12 LNs in at least 75% of 612
2 cases to evaluate hospital performance, another National Cancer Data Base study found adherence to that benchmark in only 38% of institutions in 2004 through In some studies, evaluation of a greater number of LNs has been associated with an increased likelihood of identifying patients with LN metastases Other investigators have found no association between the number of LNs evaluated and detection of stage III disease. 14,15,24 We previously evaluated factors associated with variation in LN counts with CRC resections in our institution. In that study, the number of LNs evaluated was independent of the individual surgeon, surgical specialty, case volume, and intent of the procedure (curative vs palliative) but varied with the individual pathologist as well as with patient age, comorbid illness, and tumor stage and location. 25 Other studies also have found that the surgeon is not the main variable with respect to LN yield These findings prompted us to formulate an institutional initiative to increase reported LN counts with CRC resections. We decided on a multidisciplinary approach spearheaded by our institution s cancer committee, which has representation from all specialties diagnosing and treating cancer. This led us to investigate whether (1) we could effect such a change and (2) increased LN retrieval would increase the proportion of patients with stage III CRC and/or the number of positive LNs per case, findings with the greatest potential effect on patient prognosis and selection of adjuvant therapy. METHODS In late 2004, we began a multidisciplinary institutional initiative intended to increase the reported number of LNs removed with CRC resections. We discussed unacceptably low LN counts reported with our CRC resections and reviewed the rationale for increased LN evaluation at our multidisciplinary cancer committee meeting. Our cancer liaison physician (T.J.H.) and cancer committee pathologist initiated a program of institutional awareness of these issues. Our pathologists modified their technique of LN assessment after our intervention. They used a formalin-based fat-clearing solution containing glacial acetic acid in an effort to improve LN yield. The LNs larger than 4 mm that were not grossly positive were serially sectioned. If fewer than 12 LNs were identified, the blocks were reevaluated. After approval from our institutional review committee, we then evaluated 701 consecutive operative CRC cases from January 1, 1996, through December 31, 2007, ascertained from our cancer registry. Data were confirmed by individual review of pathology reports, operative notes, and medical records. For the purpose of evaluating the effect of our cancer committee initiative, we compared early (before January 1, 2005, and our institution-wide intervention) and late (January 1, 2005, and later) patient groups. There were 553 patients in the early (preintervention) group and 148 patients in the late (postintervention) group. Data are presented as proportions (percentages) or as mean (SEM) unless otherwise stated. We used the SAS statistical package (SAS Institute Inc, Cary, North Carolina) for data analysis. We used the 2 or the Fisher exact test for analysis of categorical variables and 1-way analysis of variance, the paired t test (for normally distributed data), and the Mann-Whitney test (for nonparametric data) for continuous variables. We considered P.05 to be significant. Table 1. Comparison of Patient Demographic and Tumor Features in the Early (Preintervention) and Late (Postintervention) Periods a Variable Early Group (n=553) Late Group (n=148) P Value Age, mean (SD) 72.0 (0.5) [72] 69.6 (1.0) [70].04 [median], y Sex Male 270 (48.8) 71 (48.0) Female 283 (51.2) 77 (52.0).85 White race 530 (95.8) 120 (81.1).001 Approach Laparoscopic 40 (7.2) 66 (44.6) Open 513 (92.8) 82 (55.4).001 Tumor location Right 257 (46.5) 59 (39.9) Transverse 30 (5.4) 6 (4.1) Splenic flexure 51 (9.2) 14 (9.5).36 Sigmoid 90 (16.3) 35 (23.6) Rectal 125 (22.6) 34 (23.0) T stage In situ 29 (5.2) 14 (9.5) 1 75 (13.6) 22 (14.9) 2 85 (15.4) 19 (12.8) (57.7) 81 (54.7) 4 45 (8.1) 12 (8.1) a Unless otherwise indicated, data are expressed as number (percentage) of patients. Percentages have been rounded and may not total 100. RESULTS The median patient age was 74 (mean, 71.5 [0.5]; range, ) years. Women constituted 51.4% of the patients. Demographic, tumor, and treatment variables were similar for the early and late groups, as shown in Table 1, with the exception of younger age (median age, 70 vs 72 years), fewer white patients (81.1% vs 95.8%), and increased use of laparoscopic techniques (44.6% vs 7.2%) in the late period. For the entire study population, use of a laparoscopic technique (106 cases) was associated with retrieval of more LNs (mean, 16.1 [0.8]) than was an open approach (595 cases; mean, 13.4 [0.3] LNs). The mean number of LNs evaluated in the late period of the study, when most of the laparoscopic resections were performed, was 18.9 (1.1 [median, 22]) for the laparoscopic approach and 16 (1 [median, 22]) for the open approach (P=.06). The difference in the relative proportions of patients by T stage was not significant between the early and late groups. Overall LN counts increased from a mean of 12.8 (0.3 [median, 12]) to 17.3 (0.7 [median, 16]) (P.001), with 53.0% of patients in the early period vs 71.6% in the late period having at least 12 LNs examined (P.001). The data were stratified by T stage for the mean number of LNs evaluated, the number of positive LNs per case, and the proportion of patients with stage III disease and are summarized in Table 2. The proportion of patients with stage III disease was unchanged, with 204 of 553 (36.9%) of the early case patients and 48 of 148 (32.4%) of the late case patients having positive LNs (P=.31). The mean number of positive LNs and the proportion of patients with positive LNs with N2 disease ( 3 positive LNs) did 613
3 Table 2. Comparison of LN Data and Proportion of Patients With Stage III CRC in the Early (Preintervention) and Late (Postintervention) Periods Variable Early Group (n=553) Late Group (n=148) P Value All patients No. of LNs, mean (SEM) 12.8 (0.3) 17.3 (0.7).001 No. of positive LNs, mean (SEM) 1.7 (0.1) 1.5 (0.3).59 Stage III, No. (%) 204/553 (36.9) 48/148 (32.4).31 T1 No. of LNs, mean (SEM) 8.5 (0.8) 12.7 (1.4).01 No. of positive LNs, mean (SEM) 0.04 (0.02) 0.35 Stage III, No. (%) 3/75 (4.0) 0/22 (0).21 T2 No. of LNs, mean (SEM) 12.2 (0.9) 15.4 (1.9).14 No. of positive LNs, mean (SEM) 0.8 (0.2) 0.9 (0.5).75 Stage III, No. (%) 15/85 (17.6) 5/19 (26.3).40 T3 No. of LNs, mean (SEM) 14.3 (0.5) 19.2 (0.9).001 No. of positive LNs, mean (SEM) 2.1 (0.2) 2.2 (0.4).84 Stage III, No. (%) 154/319 (48.3) 38/81 (46.9).83 T4 No. of LNs, mean (SEM) 13.2 (1.0) 18.5 (1.9).02 No. of positive LNs, mean (SEM) 4.2 (0.7) 2.4 (1.3).23 Stage III, No. (%) 32/45 (71.1) 5/12 (41.7).06 Abbreviations: CRC, colorectal cancer; LN, lymph node. not increase from the early to late period (early, 50.5% N1 and 49.5% N2; late, 54.2% N1 and 45.8% N2). By overall tumor stage at diagnosis, the mean LN count increased significantly for each group of patients from the early to the late period. For patients with stage I disease, the mean LN count increased from 9.8 (0.6) to 14.7 (1.2) (P.001); for patients with stage II disease, from 14.4 (0.7) to 18.9 (1.3) (P=.002); and for patients with stage III disease, from 15.1 (0.7) to 18.4 (1.3) (P=.03). COMMENT The National Quality Forum recently stated that a minimum of 12 regional LNs (irrespective of tumor stage or location) should be removed and histopathologically examined with CRC resections. 30 This benchmark for defining adequate care for patients with CRC has been endorsed by multiple organizations Such mandates are intended to increase awareness of the value of LN evaluation; to allow for comparisons between hospitals, programs, surgeons, pathologists, and regions; and to permit surveillance of practice patterns and outcomes. 8,31 Although not yet a major factor affecting reimbursement or selection of providers by consumers, these data have been used by health insurance companies to select surgical providers and may be used as a quality improvement measure for monitoring and remediating performance at the hospital and systems levels. Quality measures and outcome data may be used by employers, patients, and insurers for critically evaluating physicians, hospitals, and health plans and for ranking care. Similar quality measures have been used by state health agencies and accrediting bodies to demand that providers publish their performance data for public scrutiny. 32,33 Although LN counts with CRC resection seem to be considered mainly a measure of surgical quality, multiple variables contribute to the number of LNs examined. These include variation in pathology department processing procedures, technique, diligence, and patient and tumor factors. 8,16,26-29,34,35 In fact, few data exist that justify the use of increased numbers of LNs as a quality measure that will improve cancer staging, use of chemotherapy, or patient survival. 15 Surgical resection with en bloc removal of regional mesenteric lymph nodes is the mainstay of treatment of CRC. Adjuvant chemotherapy is advised in the presence of stage III disease owing to the elevated risk of recurrence and in some high-risk patients with stage II disease and adverse prognostic features. Such treatment guidelines emphasize the importance of accurate LN staging. 4 Some authors have advised consideration of chemotherapy for patients with stage II disease in whom fewer than 12 LNs were examined. 14 Others have suggested excluding patients with CRC and fewer than 12 LNs examined from surgical adjuvant clinical trials. 10 In this study, we evaluated the impact of a multidisciplinary initiative on increasing LN evaluation in patients with CRC in an effort to increase identification of patients with LN-positive disease. After this intervention, our pathologists identified a statistically significantly greater number of LNs with our CRC resections. Before our intervention, 53% of patients underwent an adequate resection ( 12 LN). Our baseline adherence was higher than has been reported in review series that used the National Cancer Data Base or the Surveillance, Epidemiology, and End Results program The LN count increased significantly after our intervention; nearly three-quarters of our late cases included assessment of at least 12 LNs. Laparoscopic techniques were used more frequently for the late group in our study, 614
4 but this was associated with an increase, not a decrease, in LN counts. The reported data on the association between the laparoscopic vs open surgical approaches and LN yield is variable. 17,36 Overall, our improvement in LN yield demonstrates the value and impact of communication through a multidisciplinary initiative engaged in adherence to recommended standards and improving quality of care. As our pathologists examined the resected specimens, presumably with increased scrutiny, they identified a greater number of LNs but not a greater number of positive ones. Various techniques have been described to increase LN harvest. Fat clearance techniques and the use of special fixatives may improve LN yields by as much as 50%. 37 However, greater scrutiny of mesenteric nodes away from the primary tumor may focus on LNs that are less likely to contain disease. It also has been postulated that, once a positive node is noted, attentiveness to finding more nodes (positive or otherwise) decreases secondary to the perception that staging and treatment may be relatively unaltered. 15 Use of lymphatic mapping and sentinel node evaluation, although not used regularly in the clinical setting, may allow the pathologist to focus on the LN most likely to harbor metastatic disease, thereby increasing the sensitivity of LN harvest. This may result in improved staging accuracy without identification of more nodes overall, but its role is yet to be fully defined. 35 Despite the improved LN analysis in our study, we did not identify more patients with stage III disease. Before our intervention, 36.9% of our patients had LN-positive disease, whereas 32.4% were found to have positive LNs afterward. Analysis by individual T stages also failed to show any statistically significant increase in nodal positivity for the late group. Similarly, we did not see an increase in N2 disease ( 3 positive LNs) with increased LN evaluation. These data imply that our success in increasing LN yield did not result in upstaging the disease in our patients. Some have suggested that increased LN harvest is therapeutic and may improve prognosis by avoidance of understaging and failing to identify those who may benefit from adjuvant systemic therapy. 3,5,6 This association seems strong in some reviews, but whether it truly improves staging and outcomes remains unclear. 7,13-15 Some data suggest that very low LN acquisition fails to identify metastatic nodes, resulting in misclassification of stage III cancer as stage II. 22 Some investigators propose that LN counts much greater than 12 are necessary to prevent missed nodal metastases. Using the INT0089 trial data, Joseph et al 38 determined that as many as 40 LNs for T3 and 30 for T4 CRC cases need to be evaluated before one can exclude nodal metastases with an 85% certainty. Other investigators have found that adequate LN evaluation is not necessarily associated with identification of more positive nodes and dismiss understaging as a possible cause of the association between LN harvest and survival. 15,24 Lymph node yield as a quality measure places a burden on the surgeon to achieve a standard that may not be within his or her control and may not result in improved patient staging or outcome. Adoption of such standards may lead to selective contracting and public reporting. As data regarding performance are compiled, some hospitals or programs may be determined to be Centers of Excellence for CRC resection. Often such categorization is opposed by hospitals and surgeons for being unfair and not reflective of the true quality of patient care. 39 The initiation of an LN minimum as a marker of quality can lead to a varied response by physicians and systems of care. This may create a disparity for future population-based assessments of treatments and outcomes. Should reimbursement patterns change according to adherence to a given standard, efforts to encourage improved outcomes may actually fail. The carrot or stick approach has not necessarily been shown to improve performance and may reward only those who had better performance before the initiative. 40 The improved outcomes associated with higher LN counts in some studies may not necessarily be a function of clearance of the LNs per se but may be a marker of other aspects of care (eg, other technical aspects of surgical care, pathology reporting, and adjuvant therapy). It would appear advisable to investigate other such potential quality markers. For example, it may be more useful to standardize the assessment by pathologists (the process) and then set an expected standard. 31 Because prospective randomized trials show that the administration of chemotherapy for stage III disease improves survival, the validity of adjuvant chemotherapy administration to patients with stage III disease as a performance measure seems logical. In contrast, the data correlating LN counts with survival in CRC is observational and may result from unidentified confounding factors. 31 This implies that the magic number of 12 LNs might be reconsidered as the major quality indicator for the treatment of patients with CRC. To summarize, we successfully used a multidisciplinary initiative to increase LN yield with CRC resections. However, this increased LN analysis did not identify a greater number of patients with stage III disease and did not increase the proportion of patients with positive LNs and N2 disease. Our data suggest that mandatory harvest of a minimum of 12 LNs as a quality indicator or performance measure appears unfounded. Accepted for Publication: March 22, Correspondence: Tina J. Hieken, MD, Department of Surgery, Rush North Shore Medical Center, 9669 N Kenton, Ste 204, Skokie, IL (thieken@rush.edu). Author Contributions: Dr Hieken had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Kukreja and Hieken. Acquisition of data: Kukreja, Esteban-Agusti, and Hieken. Analysis and interpretation of data: Kukreja, Velasco, and Hieken. Drafting of the manuscript: Kukreja, Esteban- Agusti, and Hieken. Critical revision of the manuscript for important intellectual content: Kukreja, Velasco, and Hieken. Administrative, technical, and material support: Kukreja, Esteban-Agusti, and Hieken. Study supervision: Velasco and Hieken. Financial Disclosure: None reported. 615
5 Previous Presentation: This paper was presented at the 116th Annual Meeting of the Western Surgical Association; November 10, 2008; Santa Fe, New Mexico, and is published after peer review and revision. The discussions that follow this article are based on the originally submitted manuscript and not the revised manuscript. Additional Contributions: Maria Mikhlin, BA, RHIA, CTR, and Patricia Waldron, CTR, of the Rush North Shore Medical Center Cancer Registry maintained our cancer registry and assisted in retrieval of data and records. REFERENCES 1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, CA Cancer J Clin. 2008; 58(2): Dukes C. The classification of cancer of the rectum. J Pathol Bacteriol. 1932;35: Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT J Clin Oncol. 2003;21(15): Engstrom PF, Benson AB III, Chen YJ, et al; National Comprehensive Cancer Network. Colon cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005;3(4): Wong JH, Bowles B, Bueno R, Shimizu D. Impact of the number of negative nodes on disease-free survival in colorectal cancer patients. Dis Colon Rectum. 2002; 45(10): Johnson PM, Porter GA, Ricciardi R, Baxter N. Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol. 2006;24(22): Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst. 2007;99(6): Bilimoria KY, Stewart AK, Palis BE, Bentrem DJ, Talamonti MS, Ko CY. Adequacy and importance of lymph node evaluation for colon cancer in the elderly. J Am Coll Surg. 2008;206(2): Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer: College of American Pathologists Consensus Statement Arch Pathol Lab Med. 2000;124(7): Nelson H, Petrelli N, Carlin A, et al; National Cancer Institute Expert Panel. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst. 2001;93 (8): Cancer Care Ontario. Cancer System Quality Index. Accessed September 10, National Comprehensive Cancer Network (NCCN). ASCO/NCCN quality measures: breast and colorectal cancers. _measures. Accessed September 10, Rouffet F, Hay JM, Vacher B, et al; French Association for Surgical Research. Curative resection for left colonic carcinoma: hemicolectomy vs. segmental colectomy: a prospective, controlled, multicenter trial. Dis Colon Rectum. 1994; 37(7): Prandi M, Lionetto R, Bini A, et al. Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial. Ann Surg. 2002;235(4): Wong SL, Ji H, Hollenbeck BK, Morris AM, Baser O, Birkmeyer JD. Hospital lymph node examination rates and survival after resection for colon cancer. JAMA. 2007; 298(18): Baxter NN, Virnig DJ, Rothenberger DA, Morris AM, Jessurun J, Virnig BA. Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst. 2005;97(3): Bilimoria KY, Bentrem D, Nelson H, et al. Use and outcomes of laparoscopicassisted colectomy for cancer in the United States. Arch Surg. 2008;143(9): Bilimoria KY, Bentrem D, Stewart AK, et al. Lymph node evaluation as a colon cancer quality measure: a national hospital report card. J Natl Cancer Inst. 2008; 100(18): Maurel J, Launoy G, Grosclaude P, et al. Lymph node harvest reporting in patients with carcinoma of the large bowel: a French population-based study. Cancer. 1998;82(8): Ratto C, Sofo L, Ippoliti M, et al. Accurate lymph-node detection in colorectal specimens resected for cancer is of prognostic significance. Dis Colon Rectum. 1999;42(2): Wong JH, Severino R, Honnebier MB, Tom P, Namiki TS. Number of nodes examined and staging accuracy in colorectal carcinoma. J Clin Oncol. 1999;17 (9): Johnson PM, Malatjalian D, Porter GA. Adequacy of nodal harvest in colorectal cancer: a consecutive cohort study. J Gastrointest Surg. 2002;6(6): Swanson RS, Compton CC, Stewart AK, Bland KI. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol. 2003;10(1): Bui L, Rempel E, Reeson D, Simunovic M. Lymph node counts, rates of positive lymph nodes, and patient survival for colon cancer surgery in Ontario, Canada: a population-based study. J Surg Oncol. 2006;93(6): Choh M, Esteben-Agusti E, Velasco JM, Hieken TJ. Variation in lymph node count in colorectal cancer resections is unaffected by surgeon, specialty, volume and technique [abstract]. Ann Surg Oncol. 2008;15(S2): Derwinger K, Carlsson G, Gustavsson B. Stage migration in colorectal cancer related to improved lymph node assessment. Eur J Surg Oncol. 2007;33(7): Ostadi MA, Harnish JL, Stegienko S, Urbach DR. Factors affecting the number of lymph nodes retrieved in colorectal cancer specimens. Surg Endosc. 2007; 21(12): Rieger NA, Barnett FS, Moore JW, et al. Quality of pathology reporting impacts on lymph node yield in colon cancer [letter]. J Clin Oncol. 2007;25(4): Grote T, Hughes AH, Rimmer CC, et al. Targeting lymph node retrieval and assessment in stage II colon cancer: a quality outcome community-based cancer center study. J Oncol Pract. 2008;4(2): doi: /jop Commission on Cancer. National Quality Forum endorsed Commission on Cancer measures for quality of cancer care for breast and colorectal cancers. http: // Accessed August 28, Simunovic M, Baxter NN. Lymph node counts in colon cancer surgery: lessons for users of quality indicators [editorial]. JAMA. 2007;298(18): Schneider EC, Epstein AC. Influence of cardiac-surgery performance reports on referral practices and access to care: a survey of cardiovascular specialists. N Engl J Med. 1996;335(4): Schneider EC, Epstein A. Use of public performance reports: a survey of patients undergoing cardiac surgery. JAMA. 1998;279(20): Canessa CE, Badia F, Fierro S, Fiol V, Hayek G. Anatomic study of the lymph nodes of the mesorectum. Dis Colon Rectum. 2001;44(9): Bilchik AJ, DiNome M, Saha S, et al. Prospective multicenter trial of staging adequacy in colon cancer. Arch Surg. 2006;141(6): Lacy AM, Garcia-Valdecasas JC, Pique JM, et al. Short-term outcome analysis of a randomized study comparing laparoscopic vs open colectomy for colon cancer. Surg Endosc. 1995;9(10): Scott KW, Grace RH. Detection of lymph node metastases in colorectal carcinoma before and after fat clearance. Br J Surg. 1989;76(11): Joseph NE, Sigurdson ER, Hanlon AL, et al. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol. 2003;10(3): Birkmeyer NJ, Birkmeyer JD. Strategies for improving surgical quality: should payers reward excellence or effort? N Engl J Med. 2006;354(8): Rosenthal MB, Frank RG, Li Z, Epstein AM. Early experience with pay-forperformance, from concept to practice. JAMA. 2005;294(14): DISCUSSION Charles Scoggins, MD, MBA, Louisville, Kentucky: Dr Kukreja and colleagues have provided us with several very interesting observations. First, they clearly demonstrate the phenomenon of pathologist-related LN retrieval. We have all experienced this: when I am not satisfied with the number of nodes reported, I simply call the pathologist and order more nodes. Magically, they are able to find more. This point serves as the main stratification variable in this paper: they ordered more nodes and the pathologists responded. This has not, however, led to stage migration or the distribution of N1 and N2 disease. This is simply an observation and appears not to have affected patient care in any meaningful way. In essence, no more patients are eligible for adjuvant chemotherapy because of this change in policy at their hospital. I have 3 questions for the authors: 1. Given that quality control measures and initiatives are becoming more commonplace, including the real possibility of linkages to reimbursement, what can we as surgeons do to pro- 616
6 actively protect our interests, especially when the number of nodes found by the pathologists may not be entirely in our control? 2. Since your hospital was successful in getting your pathologists to find more LNs, how would you propose that the rest of us get our pathologists to likewise change, especially when they do not get better pay for more nodes? 3. Since more nodes did not result in stage migration or more patients who are eligible for adjuvant therapy, what benefit has this policy really provided to your patients? Dr Velasco: Thank you very much, Dr Scoggins, for your kind comments and your difficult questions. We wanted to look at the quality of care we were providing very early on. In the year 2000, we realized that we needed to get involved as an institution, we needed to take leadership, and we needed to work with other organizations such as the American College of Surgeons, the cancer committee, and the entire institution to be able to determine and define which quality measures were important. Otherwise, someone else would impose them on us. We know Blue Cross/Blue Shield, health maintenance organizations, and preferred provider organizations are active in using quality measures to grade institutions, probably soon will grade individuals, and then will use those parameters for payment for performance. Most of the studies concerning colon resection and number of LNs identified are either retrospective (as ours was), population based, or based on administrative data with information that at times is not all-inclusive. Some of the studies included diverse patients with different stages or had an insufficient number of patients. Some of the databases that have been used do not have enough information about the pathologists or the methodology. We felt that, because of all of these confounding variables, it would be important for us as an institution to look at every case consecutively and then review every chart and every pathology report individually. So the answer to the first question is that we need to run these studies based on data obtained ourselves. Now, regarding how we can get our pathologists to work with us, in our institution our pathologists are general pathologists; we don t have any gastrointestinal pathologists. What we needed to do was to involve them in the cancer committee. It really showed them that we all were being scrutinized; therefore, we needed to provide the best patient care and that we needed to examine if we are meeting some of the criteria that have been established as important. We know LN count is important and that the presence of positive LNs confers a negative prognosis. In our institution 16 surgeons perform all procedures, yet 89% of the operations were done by 6 surgeons: 1 colorectal surgeon, 1 surgical oncologist, and 4 general surgeons. Our pathologists wanted to participate; they are proud of their work. The best way is for us to have a collegial relationship and to make them part of the process. In our study, we did not find a migration of nodes into higher stages as the number of nodes identified increased. Financial Disclosure: None reported. Call for Papers Maintenance of Certification D uring 2009, we are soliciting manuscripts on maintenance of certification. The editorial board has selected this topic as our year-long theme. Accepted manuscripts will be given priority publication. Please indicate in your cover letter that your manuscript is to be considered for this theme. 617
ORIGINAL ARTICLE. Colon Cancer and Low Lymph Node Count. James W. Jakub, MD; Greg Russell, MS; Cindy L. Tillman, CTR; Craig Lariscy, MD
ORIGINAL ARTICLE Colon Cancer and Low Lymph Node Count Who Is to Blame? James W. Jakub, MD; Greg Russell, MS; Cindy L. Tillman, CTR; Craig Lariscy, MD Objective: To identify the factors that contribute
More informationLymph node ratio as a prognostic factor in stage III colon cancer
Lymph node ratio as a prognostic factor in stage III colon cancer Emad Sadaka, Alaa Maria and Mohamed El-Shebiney. Clinical Oncology department, Faculty of Medicine, Tanta University, Egypt alaamaria1@hotmail.com
More informationHospital Lymph Node Examination Rates and Survival After Resection for Colon Cancer
ORIGINAL CONTRIBUTION Hospital Lymph Node Examination Rates and Survival After Resection for Colon Cancer Sandra L. Wong, MD, MS Hong Ji, MS Brent K. Hollenbeck, MD, MS Arden M. Morris, MD, MPH Onur Baser,
More informationVariables Impacting Lymph Node Recovery in Colectomy Resection Specimens Removed for Colorectal Adenocarcinoma
Send Orders for Reprints to reprints@benthamscience.net The Open Pathology Journal, 2013, 7, 1-6 1 Open Access Variables Impacting Lymph Node Recovery in Colectomy Resection Specimens Removed for Colorectal
More informationCancer Programs Practice Profile Reports (CP 3 R) Rapid Quality Reporting System (RQRS)
O COLON MEASURE SPECIFICATIONS Cancer Programs Practice Profile Reports (CP 3 R) Rapid Quality Reporting System (RQRS) Introduction The Commission on Cancer s (CoC) National Cancer Data Base (NCDB) staff
More informationA DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY. Helen Mari Parsons
A Culture of Quality? Lymph Node Evaluation for Colon Cancer Care A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY Helen Mari Parsons IN PARTIAL FULFILLMENT
More informationPAPER. Preoperative Tattooing and Improved Lymph Node Retrieval Rates From Colectomy Specimens in Patients With Colorectal Cancers
PAPER Preoperative Tattooing and Improved Lymph Node Retrieval Rates From Colectomy Specimens in Patients With Colorectal Cancers Katie Dawson, MD; Abigail Wiebusch, MD; Richard C. Thirlby, MD Hypothesis:
More informationDifferential lymph node retrieval in rectal cancer: associated factors and effect on survival
Original Article Differential lymph node retrieval in rectal cancer: associated factors and effect on survival Cedrek McFadden 1, Brian McKinley 1, Brian Greenwell 2, Kaylee Knuckolls 1, Patrick Culumovic
More informationRegional lymph node (LN) metastasis is a strong negative
Number of Lymph Nodes in Primary Nodal Basin and a Second Look Protocol as Quality Indicators for Optimal Nodal Staging of Colon Cancer Mikhail Lisovsky, MD, PhD; Shannon N. Schutz, PA(ASCP); Michael G.
More informationThe impact of lymph node examination on survival of stage II colorectal cancer patients: Are 12 nodes adequate?
Formosan Journal of Surgery (2011) 44, 176e180 Available online at www.sciencedirect.com journal homepage: www.e-fjs.com ORIGINAL ARTICLE The impact of lymph node examination on survival of stage II colorectal
More informationStage III Colon Cancer Susquehanna Cancer Center Warren L Robinson, MD, FACP May 9, 2007
Stage III Colon Cancer Susquehanna Cancer Center 1997-21 Warren L Robinson, MD, FACP May 9, 27 Stage III Colon Cancer Susquehanna Cancer Center 1997-21 Colorectal cancer is the third most common cancer
More informationPAPER. Assessing the Quality of Colorectal Cancer Staging
PAPER Assessing the Quality of Colorectal Cancer Staging Documenting the Process in Improving the Staging of Node-Negative Colorectal Cancer Jan H. Wong, MD; D. Scott Johnson, MD; Daphne Hemmings, MD;
More informationNovel Methods of Lymph Node Evaluation for Predicting the Prognosis of Colorectal Cancer Patients with Inadequate Lymph Node Harvest
pissn 1598-2998, eissn 25-9256 Cancer Res Treat. 216;48(1):216-224 Original Article http://dx.doi.org/1.4143/crt.214.312 Open Access Novel Methods of Lymph Node Evaluation for Predicting the Prognosis
More informationCOMPARATIVE ANALYSIS OF COLON AND RECTAL CANCERS IN SENTINEL LYMPH NODE MAPPING
Trakia Journal of Sciences, Vol. 5, No. 1, pp 10-14, 2007 Copyright 2007 Trakia University Available online at: http://www.uni-sz.bg ISSN 1312-1723 Original Contribution COMPARATIVE ANALYSIS OF COLON AND
More informationGASTRIC MEASURE SPECIFICATIONS
Cancer Programs Practice Profile Reports (CP 3 R) GASTRIC MEASURE SPECIFICATIONS Introduction The Commission on Cancer s (CoC) National Cancer Data Base (NCDB) staff has undertaken an effort to improve
More informationSurvival after Complete Mesocolic Excision (CME) for Right Sided Coloncancer Compared to Standard Surgery
Send Orders for Reprints to reprints@benthamscience.net 6 The Open Surgery Journal, 213, 7, 6-1 Open Access Survival after Complete Mesocolic Excision () for Right Sided Coloncancer Compared to Standard
More informationI mproving the quality of services for colorectal cancer is a
43 ORIGINAL ARTICLE Lymph node harvests directly influence the staging of colorectal cancer: evidence from a regional audit D F H Pheby, D F Levine, R W Pitcher, N A Shepherd... See end of article for
More informationWhether regional lymph nodes evaluation should be equally required for both right and left colon cancer
/, Vol. 7, No. 37 Whether regional lymph nodes evaluation should be equally required for both right and left colon cancer Xu Guan 1,*, Wei Chen 2,*, Zheng Liu 3,*, Zheng Jiang 3, Hanqing Hu 1, Zhixun Zhao
More informationPotential Causes of Stage Migration and Their Prognostic Implications in Colon Cancer: A Nationwide Survey of Specialist Institutions in Japan
Jpn J Clin Oncol 2014;44(6)547 555 doi:10.1093/jjco/hyu043 Advance Access Publication 6 May 2014 Potential Causes of Stage Migration and Their Prognostic Implications in Colon Cancer: A Nationwide Survey
More informationUniversity of Groningen. Lymph node staging in colon cancer Kelder, Wendy
University of Groningen Lymph node staging in colon cancer Kelder, Wendy IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the
More informationLymph Node Evaluation and Survival After Curative Resection of Colon Cancer: Systematic Review
ARTICLE Lymph Node Evaluation and Survival After Curative Resection of Colon Cancer: Systematic Review George J. Chang, Miguel A. Rodriguez-Bigas, John M. Skibber, Virginia A. Moyer Background Methods
More informationClinical Significance of Lymph Node Ratio in Stage III Colorectal Cancer
Original Article Journal of the Korean Society of http://dx.doi.org/10.3393/jksc.2011.27.5.260 pissn 2093-7822 eissn 2093-7830 Clinical Significance of Lymph Node Ratio in Stage III Colorectal Cancer Yo
More informationUniversity of Groningen. Lymph node staging in colon cancer Kelder, Wendy
University of Groningen Lymph node staging in colon cancer Kelder, Wendy IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationMeasure Description. Denominator Statement
CMS ID/CMS QCDR ID: CAP 18 Title: Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Primary or Metastatic
More informationFinancial Disclosure. Learning Objectives. Review and Impact of the NCDB PUF. Moderator: Sandra Wong, MD, MS, FACS, FASCO
Review and Impact of the NCDB PUF Moderator: Sandra Wong, MD, MS, FACS, FASCO Financial Disclosure I do not have personal financial relationships with any commercial interests Learning Objectives At the
More informationThe New CP 3 R Application And Revisions To Standard 4.6 Integration Of The NCDB With The Accreditation Process
The New CP 3 R Application And Revisions To Standard 4.6 Integration Of The NCDB With The Accreditation Process Wednesday, April 29, 2009 at 11 AM Central M. Asa Carter, CTR Manager, Approvals and Standards
More informationLymph node ratio is inferior to pn-stage in predicting outcome in colon cancer patients with high numbers of analyzed lymph nodes
Jakob et al. BMC Surgery (2018) 18:81 https://doi.org/10.1186/s12893-018-0417-0 RESEARCH ARTICLE Lymph node ratio is inferior to pn-stage in predicting outcome in colon cancer patients with high numbers
More informationORIGINAL ARTICLE. International Journal of Surgery
International Journal of Surgery (2013) 11(S1), S95 S99 Contents lists available at ScienceDirect International Journal of Surgery journal homepage: www.journal-surgery.net ORIGINAL ARTICLE Impact of lymph
More informationCorporate Medical Policy
Corporate Medical Policy Multigene Expression Assay for Predicting Recurrence in Colon File Name: Origination: Last CAP Review: Next CAP Review: Last Review: multigene_expression_assay_for_predicting_recurrence_in_colon_cancer
More informationReconsideration of the optimal minimum lymph node count for young colon cancer patients: a population-based study
Guan et al. BMC Cancer (2018) 18:623 https://doi.org/10.1186/s12885-018-4428-0 RESEARCH ARTICLE Reconsideration of the optimal minimum lymph node count for young colon cancer patients: a population-based
More informationHow much colon should be resected?
Colon Cancer Surgical Standard of Care and Operative Techniques Madhulika G. Varma MD Professor and Chief Section of Colorectal Surgery University of California, San Francisco How much colon should be
More informationColorectal Cancer Dashboard
Process Risk Assessment Presence or absence of cancer in first-degree blood relatives documented for patients with colorectal cancer Percent of patients with colorectal cancer for whom presence or absence
More informationIs the number of lymph nodes retrieved in laparoscopic colorectal cancer resections related to the learning curve of the surgeon?
ORIGINAL ARTICLE Is the number of lymph nodes retrieved in laparoscopic colorectal cancer resections related to the learning curve of the surgeon? O. Aly 1, E MacDonald 2, C Watkins 2, G I Murray 3, E
More informationLaparoscopic Resection Of Colon & Rectal Cancers. R Sim Centre for Advanced Laparoscopic Surgery, TTSH
Laparoscopic Resection Of Colon & Rectal Cancers R Sim Centre for Advanced Laparoscopic Surgery, TTSH Feasibility and safety Adequacy - same radical surgery as open op. Efficacy short term benefits and
More informationNUMERATOR: Reports that include the pt category, the pn category and the histologic grade
Quality ID #100 (NQF 0392): Colorectal Cancer Resection Pathology Reporting: pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes) with Histologic Grade National Quality Strategy Domain: Effective
More informationGuidelines for Laparoscopic Resection of Curable Colon and Rectal Cancer
SAGES Society of American Gastrointestinal and Endoscopic Surgeons http://www.sages.org Guidelines for Laparoscopic Resection of Curable Colon and Rectal Cancer Author : SAGES Webmaster PREAMBLE The following
More informationCancer Center Dashboard
Cancer Center Dashboard Measure Definition Benchmark Endorsed By Screening Breast Cancer Screening Percentage of eligible women 40-69 who received a mammogram within the past 24 months NCQA reported average:
More informationCorporate Medical Policy Transanal Endoscopic Microsurgery (TEMS)
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: transanal_endoscopic_microsurgery_(tems) 6/2008 11/2018 11/2019 11/2018 Description of Procedure or Service
More information7/29/2014. Patterns of Care in Colon Cancer ( ) Literature. Background. Florida Cancer Data Compliance with NCCN Guidelines
Patterns of Care in Colon Cancer (21-212) Florida Cancer Data Compliance with FCDS Annual Meeting July 24-25, 214 Caribe Royale Resort Orlando, Florida Background O NCCN guidelines are referenced extensively
More informationUpdate on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact
Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact Bjørn Hagen, MD, PhD St Olavs Hospital Trondheim University Hospital Trondheim, Norway Endometrial Cancer (EC) The most
More informationLymph node audit on Ivor-Lewis Oesophagogastrectomy specimens - November 2013 to October 2014.
Lymph node audit on Ivor-Lewis Oesophagogastrectomy specimens - November 2013 to October 2014. Paul Malcolm, Speciality Doctor, Department of Cellular and Anatomical Pathology, Derriford Hospital, Plymouth.
More informationSurveillance of Pancreatic Cancer Patients Following Surgical Resection
Surveillance of Pancreatic Cancer Patients Following Surgical Resection Jaime Benarroch-Gampel, M.D., M.S. CERCIT Scholar CERCIT Workshops March 16, 2012 INTRODUCTION Pancreatic cancer is the 4 th leading
More informationTitle Who to treat with adjuvant therapy in Dukes B/Stage II colorectal cancer? The need for high quality pathology.
Gut Online First, published on May 9, 2007 as 10.1136/gut.2006.116830 Title Who to treat with adjuvant therapy in Dukes B/Stage II colorectal cancer? The need for high quality pathology. Authors Eva JA
More informationNUMERATOR: Reports that include the pt category, the pn category and the histologic grade
Quality ID #100 (NQF 0392): Colorectal Cancer Resection Pathology Reporting: pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes) with Histologic Grade National Quality Strategy Domain: Effective
More informationStaging and survival of colorectal cancer (CRC) in octogenarians: Nationwide Study of US Veterans
Original Article Staging and survival of colorectal cancer (CRC) in octogenarians: Nationwide Study of US Veterans Gurjiwan Sing Virk 1, Mikram Jafri 2, Syed Mehdi 3, Christopher Ashley 4 1 Department
More informationJournal of IMAB - Annual Proceeding (Scientific Papers) 2007, vol. 13, book 1
Journal of IMAB - Annual Proceeding (Scientific Papers) 2007, vol. 13, book 1 COMPARATIVE ANALYSIS OF ENDOSCOPICALY SUBMUCOSAL VS. OPEN SURGERY SUB- SEROSAL APPLICATION PATENT BLUE V INTRAOPERATIVE METHOD
More informationSentinel Lymph Node Biopsy Is Valuable For All Cancer. Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner
Sentinel Lymph Node Biopsy Is Valuable For All Cancer Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner History Lymphatics first described by Rasmus Bartholin in 1653 Rudolf Virchow postulated
More informationANNUAL REPORT. Figure 2 displays the distribution of the number of these diagnoses in 2013 by age (along the X axis) and by gender.
One ANNUAL REPORT Colorectal Cancer Colorectal cancer affects 14, Americans annually, making it the fourth most frequently diagnosed cancer in the US. It is also the second leading cause of cancer death
More informationNational Breast Cancer Audit next steps. Martin Lee
National Breast Cancer Audit next steps Martin Lee National Cancer Audits Current Bowel Cancer Head & Neck Cancer Lung cancer Oesophagogastric cancer New Prostate Cancer - undergoing procurement Breast
More informationLower lymph node yield following neoadjuvant therapy for rectal cancer has no clinical significance
Original Article Lower lymph node yield following neoadjuvant therapy for rectal cancer has no clinical significance Dedrick Kok Hong Chan 1,2, Ker-Kan Tan 1,2 1 Division of Colorectal Surgery, University
More informationLymph node harvest in rectal cancer surgery following neoadjuvant chemoradiotherapy
Journal of Surgery 2014; 2(2): 27-1 Published online April 10, 2014 (http://www.sciencepublishinggroup.com/j/js) doi: 10.1148/j.js.20140202.1 Lymph node harvest in rectal cancer surgery following neoadjuvant
More informationPosition Statement on Management of the Axilla in Patients with Invasive Breast Cancer
- Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the
More informationHigh risk stage II colon cancer
High risk stage II colon cancer Joel Gingerich, MD, FRCPC Assistant Professor Medical Oncologist University of Manitoba CancerCare Manitoba Disclaimer No conflict of interests 16 October 2010 Overview
More informationMeasure Definition Benchmark Endorsed By. Measure Definition Benchmark Endorsed By
Process Risk Assessment Tumor Site: Breast Process Presence or Risk absence Assessment of cancer in first-degree blood relatives documented in patients with invasive breast Presence cancer or absence of
More informationMethylene Blue Assisted Lymph Node Dissection in Colon Specimens. A Prospective, Randomized Study
Anatomic Pathology / Methylene Blue Assisted Lymph Node Staging Methylene Blue Assisted Lymph Node Dissection in Colon Specimens A Prospective, Randomized Study Bruno Märkl, MD, 1 Therese G. Kerwel, MD,
More informationTitle: What is the role of pre-operative PET/PET-CT in the management of patients with
Title: What is the role of pre-operative PET/PET-CT in the management of patients with potentially resectable colorectal cancer liver metastasis? Pablo E. Serrano, Julian F. Daza, Natalie M. Solis June
More informationA Measure of the Quality and Value of Standardized Genomic Testing in an Integrated Health System
A Measure of the Quality and Value of Standardized Genomic Testing in an Integrated Health System A Review From BayCare Health System Claudia Lago Toro, MD Medical Director Shimberg Breast Center St. Joseph
More informationGastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors
Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors Jaume Capdevila, MD, PhD Vall d'hebron University Hospital Vall d'hebron Institute of Oncology (VHIO)
More informationRetrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.
Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Goal of the study: 1.To assess whether patients at Truman
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationQuality Measures: How we develop them and the science behind it
Quality Measures: How we develop them and the science behind it Matthew A Facktor MD FACS Geisinger Medical Center Danville PA Sandra L Wong MD MS FACS FASCO Dartmouth Hitchcock Medical Center Lebanon
More informationTools, Reports, and Resources
Tools, Reports, and Resources What the National Cancer Database (NCDB) does for CoC-Accredited Programs By using the NCDB, CoC-accredited programs can proactively improve delivery and quality of care for
More informationT reatment for colorectal cancer is currently dictated by stage.1
1419 COLORECTAL CANCER Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology Eva J A Morris, Nicola J Maughan, David Forman, Philip Quirke... See
More informationPhysician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer
Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer Gabriela M. Vargas, MD Kristin M. Sheffield, PhD, Abhishek Parmar, MD, Yimei Han, MS, Kimberly M. Brown,
More informationTsai et al. BMC Surgery (2016) 16:17 DOI /s
Tsai et al. BMC Surgery (2016) 16:17 DOI 10.1186/s12893-016-0132-7 RESEARCH ARTICLE Factors affecting number of lymph nodes harvested and the impact of examining a minimum of 12 lymph nodes in stage I-III
More informationORIGINAL ARTICLE. Clinical Node-Negative Thick Melanoma
ORIGINAL ARTICLE Clinical Node-Negative Thick Melanoma George I. Salti, MD; Ashwin Kansagra, MD; Michael A. Warso, MD; Salve G. Ronan, MD ; Tapas K. Das Gupta, MD, PhD, DSc Background: Patients with T4
More informationMeasure Specifications Measure Description
CMS ID/CMS QCDR ID: CAP 15 Title: BRAF Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Metastatic Colorectal Adenocarcinoma Specifications Description Denominator
More informationDescription of Procedure or Service. Policy. Benefits Application
Corporate Medical Policy KRAS, NRAS, BRAF Mutation Analysis and Related File Name: Origination: Last CAP Review: Next CAP Review: Last Review: kras_nras_braf_mutation_analysis_and_related_treatment_in_metastatic_colorectal_cancer
More informationChapter 5: Epidemiology of MBC Challenges with Population-Based Statistics
Chapter 5: Epidemiology of MBC Challenges with Population-Based Statistics Musa Mayer 1 1 AdvancedBC.org, Abstract To advocate most effectively for a population of patients, they must be accurately described
More informationInitial surgery for differentiated thyroid cancer: What is the appropriate extent and attendant risks and benefits?
Initial surgery for differentiated thyroid cancer: What is the appropriate extent and attendant risks and benefits? Julie Ann Sosa, MD MA FACS Professor of Surgery and Medicine Chief, Section of Endocrine
More informationOutcome of rectal cancer after radiotherapy with a long or short waiting period before surgery, a descriptive clinical study
Original Article Outcome of rectal cancer after radiotherapy with a long or short waiting period before surgery, a descriptive clinical study Elmer E. van Eeghen 1, Frank den Boer 2, Sandra D. Bakker 1,
More informationMelanoma Quality Reporting
Melanoma Quality Reporting September 1, 2013 December 31, 2016 Laurence McCahill, MD Surgical Oncologist Metro Health Surgical Oncology Metro Health Professional Building 2122 Health Drive SW Wyoming,
More informationOutcome following surgery for colorectal cancer
Outcome following surgery for colorectal cancer Colin S McArdle* and David J Hole *University Department of Surgery, Glasgow Royal Infirmary, Glasgow and Department of Public Health, University of Glasgow,
More informationPoor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas
10 The Open Otorhinolaryngology Journal, 2011, 5, 10-14 Open Access Poor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas Kevin C. Huoh and Steven J. Wang * Head and Neck Surgery and Oncology,
More informationFollow up The way ahead. John Griffith
Follow up The way ahead John Griffith Key Emerging Principles Risk stratified pathways of care Personalised care plan and treatment summary with a hand held record Information and education Remote monitoring
More informationCOLON AND RECTAL CANCER
No disclosures COLON AND RECTAL CANCER Mark Sun, MD Clinical Assistant Professor of Surgery University of Minnesota Colon and Rectal Cancer Statistics Overall Incidence 2016 134,490 new cases 8.0% of all
More informationSurgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty
More informationRadiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience
Radiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience Poster No.: RO-0003 Congress: RANZCR FRO 2012 Type: Scientific Exhibit Authors: C. Harrington,
More informationCommunity Comprehensive Cancer Program at Swedish Covenant Hospital 2009 Annual Report reflecting 2008 statistical data
Community Comprehensive Cancer Program at Swedish Covenant Hospital 2009 Annual Report reflecting 2008 statistical data Chairman s Message K. Joseph Philip, MD Section head, Medical Oncology/Hematology
More informationCOLON CANCER FOLLOW UP GUIDELINES
COLON CANCER FOLLOW UP GUIDELINES CAGPO Dr. Raziya Mia October 1, 2016 1 DISCLOSURES NONE 2 MITIGATING POTENTIAL BIAS Recommendations are consistent with published guidelines American Society of Clinical
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abdominoperineal excision, of rectal cancer, 93 111 current controversies in, 106 109 extent of perineal dissection and removal of pelvic floor,
More informationWhat It Takes to Get Incorporation Into Guidelines and Reimbursement for Advanced Cancer Diagnostics: Lessons from Oncotype DX
What It Takes to Get Incorporation Into Guidelines and Reimbursement for Advanced Cancer Diagnostics: Lessons from Oncotype DX WSMOS Meeting Oct 2013 Steven Shak, MD Genomic Health Disclosure: October
More informationEsophageal cancer: Biology, natural history, staging and therapeutic options
EGEUS 2nd Meeting Esophageal cancer: Biology, natural history, staging and therapeutic options Michael Bau Mortensen MD, Ph.D. Associate Professor of Surgery Centre for Surgical Ultrasound, Upper GI Section,
More informationCON: Removal of the Breast Primary in Patients with Metastatic Breast Cancer
CON: Removal of the Breast Primary in Patients with Metastatic Breast Cancer Amelia B. Zelnak, M.D., M.Sc. Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute Emory University
More informationThe effect of delayed adjuvant chemotherapy on relapse of triplenegative
Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,
More informationAJCC 7 th Edition Staging Disease Site Webinar Colorectum
AJCC 7 th Edition Staging Disease Site Webinar Colorectum Donna M. Gress, RHIT, CTR Validating science. Improving patient care. This presentation was supported by the Cooperative Agreement Number DP13-1310
More information7 th Edition Staging. AJCC 7 th Edition Staging. Disease Site Webinar. Colorectum. Overview. This webinar is sponsored by
AJCC 7 th Edition Staging Colorectum Donna M. Gress, RHIT, CTR Validating science. Improving patient care. This presentation was supported by the Cooperative Agreement Number DP13-1310 from The Centers
More informationCOLON AND RECTAL CANCER
COLON AND RECTAL CANCER Mark Sun, MD Clinical Associate Professor of Surgery University of Minnesota No disclosures Objectives 1) Understand the epidemiology, management, and prognosis of colon and rectal
More informationNUMERATOR: Reports that include the pt category, the pn category and the histologic grade
Quality ID #99 (NQF 0391): Breast Cancer Resection Pathology Reporting: pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes) with Histologic Grade National Quality Strategy Domain: Effective
More informationRebecca Vogel, PGY-4 March 5, 2012
Rebecca Vogel, PGY-4 March 5, 2012 Historical Perspective Changes In The Staging System Studies That Started The Talk Where We Go From Here Cutaneous melanoma has become an increasingly growing problem,
More informationAcing the Test: Implementing Best Practices for the Use of Molecular Testing in the Community Setting
Acing the Test: Implementing Best Practices for the Use of Molecular Testing in the Community Setting Disclosures I do not intend to discuss an off-label use of a product during this activity I have not
More informationCollege of American Pathologists (CAP)/ Physician Consortium for Performance Improvement. Pathology Physician Performance Measurement Set
College of American Pathologists (CAP)/ Physician Consortium for Performance Improvement Pathology Physician Performance Measurement Set Approved by the Consortium June 1, 2007 Pathology Work Group David
More informationSurgery for gallbladder cancer in the US: a need for greater lymph node clearance
Original Article Surgery for gallbladder cancer in the US: a need for greater lymph node clearance Thuy B. Tran 1,2, Nicholas N. Nissen 1 1 Department of Surgery, Stanford University, Stanford, CA, USA;
More informationDelay of Treatment Initiation Does Not Adversely Affect Survival Outcome in Breast Cancer
pissn 1598-2998, eissn 25-9256 Cancer Res Treat. 216;48(3):962-969 Original Article http://dx.doi.org/1.4143/crt.215.173 Open Access Delay of Treatment Initiation Does Not Adversely Affect Survival Outcome
More informationPAPER. Effect of Hospital Type and Volume on Lymph Node Evaluation for Gastric and Pancreatic Cancer
PAPER Effect of Hospital Type and Volume on Lymph Node Evaluation for Gastric and Pancreatic Cancer Karl Y. Bilimoria, MD, MS; Mark S. Talamonti, MD; Jeffrey D. Wayne, MD; James S. Tomlinson, MD; Andrew
More informationStage: The Language of Cancer
Stage: The Language of Cancer American Joint Committee on Cancer American College of Surgeons Chicago, IL Validating science. Improving patient care. No materials in this presentation may be repurposed
More informationGeneral Information. Please silence cell phones. Locations Restrooms to the left of the ballroom, or to your right by the elevators
American American College College of of Surgeons 2013 Content 2014 Content cannot be be reproduced or or repurposed without written permission of of the the American College College of Surgeons. of Surgeons.
More informationTalk to Your Doctor. Fact Sheet
Talk to Your Doctor Hearing the words you have skin cancer is overwhelming and would leave anyone with a lot of questions. If you have been diagnosed with Stage I or II cutaneous melanoma with no apparent
More information